<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="220063">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219076</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2305</org_study_id>
    <nct_id>NCT00219076</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients</brief_title>
  <official_title>A Six-Week, Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren 150 mg and Amlodipine 5 mg Compared to Amlodipine 5 mg and 10 mg in Hypertensive Patients Not Adequately Responsive to Amlodipine 5 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To evaluate the blood pressure lowering effect and safety of aliskiren 150 mg used in
      combination with amlodipine 5 mg in patients with essential hypertension not adequately
      responsive to amlodipine 5 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean sitting diastolic blood pressure after 6 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sitting systolic blood pressure after 6 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean sitting diastolic blood pressure &lt; 90 mmHg or a reduction of &gt; 10 mmHg after 6 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieve mean sitting blood pressure target of &lt; 140/90 mmHg after 6 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in standing diastolic blood pressure after 6 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in standing systolic blood pressure after 6 weeks</measure>
  </secondary_outcome>
  <enrollment>504</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aliskiren</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients with essential hypertension

          -  Patients who are eligible and able to participate in the study Exclusion Criteria

          -  Severe hypertension

          -  History or evidence of a secondary form of hypertension

          -  History of Hypertensive encephalopathy or cerebrovascular accident. Other
             protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Investigative Centers</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <lastchanged_date>September 25, 2008</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <keyword>Hypertension, aliskiren, blood pressure, amlodipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
